Document ID: /roh_data/filtered/swiss_laws_in_ROHinterleaved.jsonl.gz/34912

This text was translated from EN into Rumantsch Grischun.

The Federal Council shall specify how long the exceptional licences issued under the previous law by the FOPH for the import, production and placing on the market of narcotics containing an effective concentration of cannabis for medical purposes remain valid after the Amendment of 19 March 2021 comes into force. For as long as the exceptional licence in accordance with paragraph 1 remains valid, no licence is required from Swissmedic under Article 4. Inserted by No I of the FA of 19 March 2021, in force since 1 Aug. 2022  (AS 2022 385; BBl 2020 6069).

Il Cussegl federal fixescha, quant ditg che las permissiuns excepziunalas ch’il UFSP ha concedì tenor il dretg vertent per cultivar, per importar, per producir e per metter en circulaziun narcotics dal tip da cannabis per intents medicinals restan valaivlas suenter l’entrada en vigur da la midada dals 19 da mars 2021. Uschè ditg che la permissiun excepziunala tenor l’alinea 1 è valaivla, na dovri betg ina permissiun da Swissmedic tenor l’artitgel 4. Integrà tras la cifra I da la LF dals 19 da mars 2021, en vigur dapi il 1. d’avust 2022 (AS 2022 385; BBl 2020 6069).